Understanding how immune checkpoint inhibitors interact with other medications
Official title: Investigation of the Immune-Mediated Drug-Drug Interaction Potential of Immune Checkpoint Inhibitors
Funded at Indiana University Indianapolis · NIH-10896252 · Data updated 2026-11-12
This study is looking at how cancer treatments called immune checkpoint inhibitors might interact with other medications you’re taking, to help make sure they work safely and effectively together.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | August 15, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $167,256 |
| NIH project number | 5K23GM147805-03 |
| Project ID | NIH-10896252 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients receiving immune checkpoint inhibitors who are also taking other medications.
✕Less likely to help
Patients who are not undergoing treatment with immune checkpoint inhibitors or who are not taking any other medications may not benefit from this research.
What this research studies
This research investigates how immune checkpoint inhibitors, which are used in cancer treatment, may interact with other medications that patients are taking. It focuses on the role of pro-inflammatory cytokines produced during treatment, which can affect liver enzymes responsible for drug metabolism. By identifying potential drug-drug interactions, the research aims to reduce adverse events and improve the safety and effectiveness of checkpoint inhibitor therapies for patients. The approach includes analyzing patient data and conducting assays to discover these interactions.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments by minimizing adverse effects associated with immune checkpoint inhibitors.
How similar studies have gone: Previous studies have indicated that drug-drug interactions can significantly impact the safety of cancer therapies, suggesting that this research could build on established findings.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Shugg, Tyler a — Indiana University Indianapolis
- Study coordinator: Shugg, Tyler a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Gut bacteria that can make cancer immunotherapy less effective
This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.
-
Decoding how NSCLC patients respond and react to immunotherapy through noninvasive blood tests and tumor samples
A study in people with non-small cell lung cancer will look at blood and tumor samples to understand why some patients benefit from immunotherapy and who might have serious side effects.
-
Understanding skin reactions from immune cancer drugs and how our body’s immune system reacts to them
This grant explores why some people develop severe skin reactions when treated with immune checkpoint inhibitors and aims to use patient data and tissue studies to improve care.
-
Targeting NNMT in the tumor environment to make immunotherapy work better
Aiming to boost cancer treatment by blocking NNMT in the tumor’s supportive tissue so immune therapies work more effectively.
-
Using JAK inhibitors to calm autoimmune damage from cancer immunotherapy
A multi-center, early-phase trial will test whether a JAK inhibitor can help people who develop diabetes caused by cancer immunotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.